Get started
Author

Scott D. Lunin

The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL
2018 · Ian W. Flinn, Peter Hillmen, et al. · Blood · 342
PDF
DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma
2019 · Ian W. Flinn, Carole B. Miller, et al. · Journal of Clinical Oncology · 265
Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
2018 · Michele Maio, Karl Lewis, et al. · The Lancet Oncology · 215
Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial
2019 · Guillermo Garcia-Manero, Gail Roboz, et al. · The Lancet Haematology · 95
Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia
2017 · Gail J. Roboz, Hagop M. Kantarjian, et al. · Cancer · 66
PDF
Identification of overlapping epitopes in mutant ras oncogene peptides that activate CD4+ and CD8+ T cell responses
1996 · Scott I. Abrams, Stephen F. Stanziale, et al. · European Journal of Immunology · 60
PDF
Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial
2021 · Jeff P Sharman, Danielle M Brander, et al. · The Lancet Haematology · 50
Neoadjuvant chemotherapy/gefitinib followed by concurrent chemotherapy/radiation therapy/gefitinib for patients with locally advanced squamous carcinoma of the head and neck
2009 · John D. Hainsworth, David R. Spigel, et al. · Cancer · 44
Clinical relevance of VEGF receptors 1 and 2 in patients with chronic myelogenous leukemia
2003 · Srdan Verstovsek, Scott Lunin, et al. · Leukemia Research · 36
Rituximab With or Without Bevacizumab for the Treatment of Patients With Relapsed Follicular Lymphoma
2014 · John D. Hainsworth, F. Anthony Greco, et al. · Clinical Lymphoma Myeloma & Leukemia · 27
Dynamo: A Phase 2 Study Demonstrating the Clinical Activity of Duvelisib in Patients with Relapsed Refractory Indolent Non-Hodgkin Lymphoma
2016 · Ian W. Flinn, Carole B. Miller, et al. · Blood · 25
Induction chemotherapy + gefitinib followed by concurrent chemotherapy/radiation therapy/gefitinib for patients (pts) with locally advanced squamous carcinoma of the head and neck: A phase I/II trial of the Minnie Pearl Cancer Research Network
2006 · H. H. Doss, F. A. Greco, et al. · Journal of Clinical Oncology · 23
DYNAMO: a PHASE 2 STUDY DEMONSTRATING THE CLINICAL ACTIVITY OF DUVELISIB IN PATIENTS WITH DOUBLE‐REFRACTORY INDOLENT NON‐HODGKIN LYMPHOMA
2017 · P. Zinzani, N. Wagner‐Johnston, et al. · Hematological Oncology · 16
PDF
Effect of adding ublituximab to ibrutinib on PFS, ORR, and MRD negativity in previously treated high-risk chronic lymphocytic leukemia: Final results of the GENUINE phase III study.
2020 · Jeff P. Sharman, Danielle M. Brander, et al. · Journal of Clinical Oncology · 9
First Clinical Results of a Randomized Phase 2 Dose-Response Study of SGI-110, a Novel Subcutaneous (SC) Hypomethylating Agent (HMA), in 102 Patients with Intermediate (Int) or High Risk (HR) Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML)
2014 · Guillermo Garcia-Manero, Ellen K. Ritchie, et al. · Blood · 9
Ublituximab and ibrutinib for previously treated genetically high-risk chronic lymphocytic leukemia: Results of the GENUINE phase 3 study.
2017 · Jeff Porter Sharman, Danielle M. Brander, et al. · Journal of Clinical Oncology · 7
Ublituximab and Ibrutinib for Previously Treated Genetically High‐risk Chronic Lymphocytic Leukemia: Results of the Genuine Phase 3 Study
2017 · J.P. Sharman, D.M. Brander, et al. · Hematological Oncology · 6
First results of a phase 2 study using a 10-day subcutaneous (SC) regimen of the novel hypomethylating agent (HMA) SGI-110 for the treatment of relapsed/refractory acute myeloid leukemia (r/r AML).
2014 · Elizabeth A. Griffiths, Hagop M. Kantarjian, et al. · Journal of Clinical Oncology · 6
Phase II trial of vinflunine in patients with relapsed small cell lung cancer
2007 · J. D. Peyton, D. R. Spigel, et al. · Journal of Clinical Oncology · 6
Long Term Results of a Randomized Phase 2 Dose-Response Study of Guadecitabine, a Novel Subcutaneous (SC) Hypomethylating Agent (HMA), in 102 Patients with Intermediate or High Risk Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML)
2018 · Guillermo Garcia-Manero, Ellen K. Ritchie, et al. · Blood · 5
Results from the phase 3 DUOTM trial : a randomized comparison of duvelisib vs ofatumumab in patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma
2017 · Flinn, Ian W, Hillmen, Peter, et al. · Ghent University Academic Bibliography (Ghent University) · 5
Landmark Response and Survival Analyses from 102 MDS and CMML Patients Treated with Guadecitabine in a Phase 2 Study Showing That Maximum Response and Survival Is Best Achieved with Adequate Treatment Duration
2019 · Michael R. Savona, Hagop M. Kantarjian, et al. · Blood · 3
A Phase II Trial Evaluating the Safety of Rapid Infusion of Ofatumumab in Patients with Previously Treated Chronic Lymphocytic Leukemia
2017 · William Donnellan, Jesus G. Berdeja, et al. · The Oncologist · 3
PDF
Duvelisib inhibition of chemokines in patients with CLL (DUO study) and iNHL (DYNAMO study).
2018 · David T. Weaver, Kam Sprott, et al. · Journal of Clinical Oncology · 2
Suppurative Parotitis
2001 · Scott D. Lunin, Stephan Moll · New England Journal of Medicine · 2
Works count: 32
Citation count: 1,330
H-index: 13
I10-index: 13
Year
Topic
Type